From the Journals

SMART-CHOICE 3-year results support dropping aspirin after PCI


 

FROM JAMA CARDIOLOGY

P2Y12-inhibitor monotherapy ‘attractive concept’

In an accompanying editor’s note, Ajay Kirtane, MD, Columbia University Irving Medical Center/New York–Presbyterian Hospital, New York, and Roxana Mehran, MD, Icahn School of Medicine at Mount Sinai and the Cardiovascular Research Foundation, New York, note that current guidelines recommend 3-6 months of DAPT following PCI with current-generation drug-eluting stents in stable patients and 6-12 months or longer for those with acute coronary syndromes. For patients at higher risk of bleeding, even shorter DAPT durations can be considered on a case-by-case basis.

Historically, the component of DAPT subject to discontinuation decisions was the P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor), but more recent trials have further explored whether discontinuation of the aspirin component of DAPT can mitigate bleeding while preserving anti-ischemic efficacy.

The editorialists explain that the concept of P2Y1-inhibitor monotherapy is attractive because it may optimize antiplatelet effects through a single agent that can avoid the gastrointestinal toxicity of aspirin as well as the increased bleeding that comes with combing multiple antithrombotic agents.

They suggest that the long-term results from the SMART-CHOICE trial “should lead clinicians to consider a strategy of monotherapy after a short period of DAPT as a viable one to mitigate bleeding risk,” although they also point out that SMART-CHOICE was underpowered to rigorously assess ischemic differences, so caution is warranted.

“For patients at greatest risk for recurrent ischemic events, the role of continued DAPT is always an option, but these data (and other consistent trials) give clinicians more options to pursue individualized treatment decisions,” they write.

“To some, the continually moving field of post-PCI antiplatelet therapy has provided too many choices, which can at times be dizzying. To us, every patient is different, and thoughtful evidence-based consideration is increasingly possible for many of our treatment decisions,” they conclude.

The SMART-CHOICE study was supported by unrestricted grants from the Korean Society of Interventional Cardiology, Abbott Vascular, Biotronik, and Boston Scientific.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Does DTC heart drug advertising discourage lifestyle changes?
Journal of Clinical Outcomes Management
Multibiomarker risk score predicts complex revascularization
Journal of Clinical Outcomes Management
In blinded trial, artificial intelligence beats sonographers for echo accuracy
Journal of Clinical Outcomes Management
DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening
Journal of Clinical Outcomes Management
No benefit of routine stress test POST-PCI in high-risk patients
Journal of Clinical Outcomes Management
Artificial sweeteners linked to higher CV event risk
Journal of Clinical Outcomes Management
ACC/AHA issue chest pain data standards update to 2021 guideline
Journal of Clinical Outcomes Management
No invasive strategy benefit at 5 years in ISCHEMIA-CKD extension study
Journal of Clinical Outcomes Management
Heparin pretreatment may safely open arteries before STEMI cath
Journal of Clinical Outcomes Management
TAVR now used in almost 50% of younger severe aortic stenosis patients
Journal of Clinical Outcomes Management